BOW vs REGN · P/E 16, rev $425.7M vs P/E 14, rev $14.34B
Bowhead Specialty Holdings Inc. (BOW) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Bowhead Specialty Holdings Inc. (BOW) is a insurance - property & casualty company listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported BOW revenue for 2024-12-31 was $425.7M. Net income was $38.2M. Revenue was up 50.2% from 2023-12-31 to 2024-12-31. BOW currently screens at market cap $903.7M and trailing P/E 15.9.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
BOW currently screens at market cap $903.7M and trailing P/E 15.9. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the BOW and REGN stock pages for the full models.
Not investment advice.